UTMD · Utah Medical Products Inc
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 2026 YTD ROE (before dividends) | 9% | YTD 2026 | — |
| adjusted consolidated EBITDA non-GAAP | $7.57M | 1H 2026 | — |
| adjusted consolidated trailing twelve months' (TTM) EBITDA non-GAAP | $15.7M | TTM as of June 30, 2026 | — |
| Average Inventory Turns (based on 2Q 2026 CGS) | 1.7 | as of June 30, 2026 | — |
| Current Ratio | 48.6 | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UTMD
this stock
Utah Medical Products Inc
|
$227.39M | +27.6% | -5.8% | 21.8 | 4.3% |
|
ISRG
Intuitive Surgical Inc
|
$140.51B | -33.9% | +20.5% | 45.7 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$51.11B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$44.58B | -22.4% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.25B | -7.5% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UTMD | -0.9% | +11.3% | +7.2% | +1.3% | +27.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.0% | +8.0% | -4.0% | -0.8% | +15.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.